Last reviewed · How we verify
DI-Leu16-IL2 immunocytokine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
DI-Leu16-IL2 immunocytokine (DI-Leu16-IL2 immunocytokine) — City of Hope Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DI-Leu16-IL2 immunocytokine TARGET | DI-Leu16-IL2 immunocytokine | City of Hope Medical Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DI-Leu16-IL2 immunocytokine CI watch — RSS
- DI-Leu16-IL2 immunocytokine CI watch — Atom
- DI-Leu16-IL2 immunocytokine CI watch — JSON
- DI-Leu16-IL2 immunocytokine alone — RSS
Cite this brief
Drug Landscape (2026). DI-Leu16-IL2 immunocytokine — Competitive Intelligence Brief. https://druglandscape.com/ci/di-leu16-il2-immunocytokine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab